ACIU

AC Immune SA

3.27 USD
-0.01 (-0.30%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AC Immune SA stock is down -18.25% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 February’s closed higher than January.

About AC Immune SA

AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.